• Aleksi Šedo
    Biomedical science is trying to find ways to help patients whom clinical medicine so far cannot help.
    Aleksi Šedo
  • Ondřej Slabý
    Cancer research that really helps is always based on intensive interdisciplinary collaboration.
    Ondřej Slabý
  • Marián Hajdúch
    Our research teams make constant, incremental progress in both diagnosing and treating cancers – and they will never give up in fighting this enemy.
    Marián Hajdúch
3nodes

Prague, Brno, Olomouc

5

research programmes

11

research institutes

71

research teams

1shared goal

progress in the fight against cancer

About us


Research of cancers represents about 25% of all biomedical research in the Czech Republic. It is an area that has a long tradition in our country and its current results are, in international comparison, above the average.


Details

News and announcements

25. 7. 2025

4EU+ Against Cancer Summer School returned for the third time – this year at the Sorbonne!

Three days of an intensive program, top lecturers, professionals from various fields of academic and clinical oncology representing several European universities, and over 30 students who were not afraid to tackle challenging topics such as preclinical research, drug development, or bioinformatics. That was the 4EU+ Against Cancer Summer School – a project of the European University Alliance 4EU+, with Czech contributions to the academic program provided by researchers from the National Institute for Cancer Research (NICR).
19. 7. 2025

Successful Summer School of Experimental Surgery!

From June 30 to July 11, 2025, the 12th annual Summer School of Experimental Surgery took place at the Faculty of Medicine of Charles University in Pilsen. This prestigious international educational event is traditionally organized by a team led by Václav Liška, whose research group is part of the NICR.

Collaboration


In addition to several large European and Czech scientific infrastructures, the National Institute for Cancer Research will also cooperate with various university hospitals, pharmaceutic or biotechnological companies, patient organisations, and other partners.


Details